New treatment of ulcerative colitis with K-76.
The complement inhibitor K-76 (Otsuka Pharmaceutical Co., Osaka, Japan) was clinically evaluated as a new drug for treatment of active stage ulcerative colitis (UC). As monotherapy, K-76 proved effective in four of five cases. Furthermore, in patients with active stage UC that continued despite administration of corticosteroid hormone and salicylazosulphapyridine (so-called refractory UC), concomitant administration of K-76 was effective in seven of 21 cases. Thus, we believe that the multifunctional agent K-76 will provide clinicians with a new therapeutic approach to inflammatory bowel diseases, including UC and Crohn's disease.
Kitano
A
A
3rd Department of Internal Medicine, Osaka City University Medical School, Japan.
Matsumoto
T
T
Nakamura
S
S
Obata
A
A
Oshitani
N
N
Okawa
K
K
Kobayashi
K
K
D000293:Adolescent; D000328:Adult; D002648:Child; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006877:Hydroxamic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D006877:Hydroxamic Acids; C003486:2-methyl-3-(4-phenylpiperidino)propionohydroxamic acid hydrochloride